EMD 57439

Drug Profile

EMD 57439

Latest Information Update: 17 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Nonindustrial source; Roche Palo Alto LLC
  • Class Cardiotonics; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 09 Nov 1999 Preclinical development for Congestive heart failure in Japan (Unknown route)
  • 09 Nov 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 12 Aug 1998 No-Development-Reported for Heart failure in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top